PHATHOM PHARMACEUTICALS, INC. Contract with Customer, Receivable, after Allowance for Credit Loss
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Contract with Customer, Receivable, after Allowance for Credit Loss of $96.42 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $96.42M.
- 2026-03-31: Contract with Customer, Receivable, after Allowance for Credit Loss $73.86M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss $76.11M.
- 2025-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss $53.45M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $96.42M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $73.86M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $76.11M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $53.45M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $48.22M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $34.84M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $35.65M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.30M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |